Arbutus Biopharma Number Of Shares Shorted vs. Return On Asset
| ABUS Stock | USD 2.98 0.09 3.11% |
For Arbutus Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Arbutus Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Arbutus Biopharma Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Arbutus Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Arbutus Biopharma Corp over time as well as its relative position and ranking within its peers.
Arbutus |
Arbutus Biopharma's Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Arbutus Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.077 | Quarterly Revenue Growth (0.77) | Return On Assets (0.29) | Return On Equity (0.58) |
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Arbutus Biopharma Corp Return On Asset vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Arbutus Biopharma's current stock value. Our valuation model uses many indicators to compare Arbutus Biopharma value to that of its competitors to determine the firm's financial worth. Arbutus Biopharma Corp is number one stock in number of shares shorted category among related companies. It is number one stock in return on asset category among related companies . Return On Assets is likely to drop to -0.53 in 2024. Comparative valuation analysis is a catch-all model that can be used if you cannot value Arbutus Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Arbutus Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arbutus Biopharma's earnings, one of the primary drivers of an investment's value.Arbutus Return On Asset vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Arbutus Biopharma |
| = | 5.81 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Arbutus Biopharma |
| = | -0.29 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Arbutus Return On Asset Comparison
Arbutus Biopharma is currently under evaluation in return on asset category among related companies.
Arbutus Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Arbutus Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Arbutus Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Arbutus Biopharma's change in net profit over the period of time. It can combine multiple indicators of Arbutus Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -48.4 M | -46 M | |
| Operating Income | -78 M | -81.9 M | |
| Net Loss | -72.8 M | -76.5 M | |
| Net Loss | -75.5 M | -71.7 M | |
| Income Before Tax | -72.8 M | -76.5 M | |
| Total Other Income Expense Net | 5.2 M | 5.4 M | |
| Net Loss | -62.5 M | -65.6 M | |
| Income Tax Expense | (1.00) | (1.05) | |
| Non Operating Income Net Other | 2.5 M | 2.4 M | |
| Interest Income | 5.2 M | 3.7 M | |
| Net Interest Income | 4.4 M | 4.7 M | |
| Change To Netincome | 2 M | 1.9 M | |
| Net Loss | (0.44) | (0.46) | |
| Income Quality | 1.18 | 0.83 | |
| Net Income Per E B T | 0.96 | 0.76 |
Arbutus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Arbutus Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Arbutus Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Arbutus Biopharma's important profitability drivers and their relationship over time.
Use Arbutus Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arbutus Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arbutus Biopharma will appreciate offsetting losses from the drop in the long position's value.Arbutus Biopharma Pair Trading
Arbutus Biopharma Corp Pair Trading Analysis
The ability to find closely correlated positions to Arbutus Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arbutus Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arbutus Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arbutus Biopharma Corp to buy it.
The correlation of Arbutus Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arbutus Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arbutus Biopharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arbutus Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Arbutus Biopharma position
In addition to having Arbutus Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Restaurants Thematic Idea Now
Restaurants
Entities that are involved in restaurant business, as well as coffee shop chains and other eateries. The Restaurants theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaurants Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Arbutus Stock analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
To fully project Arbutus Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Arbutus Biopharma Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Arbutus Biopharma's income statement, its balance sheet, and the statement of cash flows.